Final results from Telaprevir (TVR) phase II studies in genotype 1 treatment – naive or experienced subjects with chronic hepatitis C

T. Berg, T. Goeser, P. Buggisch, S. Mauss, H. Wedemeyer, M. Beumont, C. Vogt & S. Zeuzem
Introduction and objectives: Current standard of care (SOC) for treatment of HCV Genotype 1 (G1) naïve patients comprises of pegylated interferon (P) plus ribavirin (R) for 48 weeks resulting in a sustained viral response (SVR) of 42 to 46% in treated patients. Telaprevir (TVR) is a novel [for full text, please go to the a.m. URL]